S&N, in their presentation, announced that it has agreed to acquire Osiris Therapeutics, a fast growing company delivering regenerative medicine products, including skin, bone graft and articular cartilage substitutes, for $19.00 per share in cash, representing a total equity value of approximately $660 million, and referenced SmartTRAK Market Research as their source for Grafix and Stravix participation numbers in the US skin substitute market, reporting that they are currently worth $900MM per annum and growing 7% annually.
SmartTRAK is the leading source of competitive intelligence used by the top ten global orthopedic & wound care companies. If you would like a demo of what SmartTRAK has to offer and how we can help increase proficiency, improve productivity and reduce costs for your company, just click the button below.